DOI:
10.1055/s-00034915
Onkologische Welt
LinksClose Window
References
Schuster SJ. et al
Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines.
ASH 2019 Abstract 6
Access:
We do not assume any responsibility for the contents of the web pages of other providers.